Therapeutic effects of Mae-Al-Osoul syrup in infertile women with polycystic ovary syndrome

Investigating the therapeutic effects of Mae-Al-Osoul syrup on biochemical factors and sex hormones in infertile women with polycystic ovary syndrome.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170923036334N7

Enrollment

Registered

2025-12-17

Start date

2025-12-22

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary. Sclerocystic ovary syndrome

Interventions

Intervention 1: Intervention group: 20 patients with polycystic ovary syndrome will use Ma'al-Asul syrup, which is prepared from Buali Daroo Company. How to take the medicine: They will receive one do

Eligibility

Sex/Gender

Female

Age

25 Years to 35 Years

Inclusion criteria

Inclusion criteria: Normality of a partner's sperm analysis Normal thyroid function and prolactin levels Normal hysterosalpingography Absence of endometriosis

Exclusion criteria

Exclusion criteria: Lack of ovulation Male factor infertility Congenital adrenal hyperplasia Thyroid dysfunction Pelvic organ injuries, Cushing's syndrome, severe liver or kidney disease, or active stomach ulcers

Design outcomes

Primary

Measure	Time frame
Blood sugar measurement. Timepoint: 6-8 weeks after taking the drug. Method of measurement: This test is performed using a photometric kit for the quantitative detection of glucose in serum or plasma.;Measuring malondialdehyde concentration. Timepoint: 6-8 weeks after taking the drug. Method of measurement: Using a commercial kit and ELISA method.;Measuring total antioxidant capacity. Timepoint: 6-8 weeks after taking the drug. Method of measurement: Using a commercial kit and ELISA method.;Superoxide dismutase assay. Timepoint: 6-8 weeks after taking the drug. Method of measurement: Using a commercial kit and ELISA method.;Glutathione peroxidase assay. Timepoint: 6-8 weeks after taking the drug. Method of measurement: Using a commercial kit and ELISA method.	—

Measure

Time frame

Blood sugar measurement. Timepoint: 6-8 weeks after taking the drug. Method of measurement: This test is performed using a photometric kit for the quantitative detection of glucose in serum or plasma.;Measuring malondialdehyde concentration. Timepoint: 6-8 weeks after taking the drug. Method of measurement: Using a commercial kit and ELISA method.;Measuring total antioxidant capacity. Timepoint: 6-8 weeks after taking the drug. Method of measurement: Using a commercial kit and ELISA method.;Superoxide dismutase assay. Timepoint: 6-8 weeks after taking the drug. Method of measurement: Using a commercial kit and ELISA method.;Glutathione peroxidase assay. Timepoint: 6-8 weeks after taking the drug. Method of measurement: Using a commercial kit and ELISA method.

—

Secondary

Measure	Time frame
FSH hormone measurement. Timepoint: 6-8 weeks after taking the drug. Method of measurement: Measuring FSH hormone levels using commercial ELISA kits.;LH hormone measurement. Timepoint: 6-8 weeks after taking the drug. Method of measurement: Measuring LH hormone levels using commercial ELISA kits.;Testosterone hormone measurement. Timepoint: 6-8 weeks after taking the drug. Method of measurement: Measurement of testosterone levels using commercial ELISA kits.	—

Measure

Time frame

FSH hormone measurement. Timepoint: 6-8 weeks after taking the drug. Method of measurement: Measuring FSH hormone levels using commercial ELISA kits.;LH hormone measurement. Timepoint: 6-8 weeks after taking the drug. Method of measurement: Measuring LH hormone levels using commercial ELISA kits.;Testosterone hormone measurement. Timepoint: 6-8 weeks after taking the drug. Method of measurement: Measurement of testosterone levels using commercial ELISA kits.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtefeh verdi

Iranian academic center for education culture and research

Atefeh.verdi@yahoo.com+98 25 3270 0155

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026